Gastrointestinal Cancers (Issue 3)

James C. Yao, MD, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).

Selection of first-line treatments and the rational sequencing of therapies are the focus of current research in the treatment of pancreatic neuroendocrine tumors (NETs).

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).

Using more accurately defined data than previous studies, a team of investigators at the UCSD School of Medicine has characterized the epidemiology of GIST.

The number of therapies available for the treatment of metastatic colorectal cancer (mCRC) has increased dramatically since the mid-1990s, when the only option approved by the FDA was 5-fluorouracil (5-FU).

Hepatocellular carcinoma remains one of the most common tumors worldwide, and frequently carries a poor prognosis, with most patients being diagnosed at late stages of disease.

As with most cancers, early diagnosis and treatment of hepatocellular carcinoma (HCC) may result in more effective treatment and improved outcomes. Unfortunately, most patients with HCC are diagnosed at a late stage, when therapeutic options are limited and prognosis is poor.

Tanios Bekaii-Saab, MD, discusses the future of immunotherapy and viral therapy for the treatment of pancreatic cancer.